Skin Metastases from Neuroendocrine Tumors Can Respond to Targeted Peptide Radionuclide Therapy (PRRT) | Research

The takeaway

Cutaneous metastases from visceral neuroendocrine tumors are rare but can respond to surgical resection and peptide receptor radionuclide therapy (PRRT), highlighting the importance of histologic diagnosis.

Extremely rare
Cutaneous metastases from visceral NETs, treated successfully with PRRT and surgery

What the researchers found

Cutaneous neuroendocrine metastases from visceral origins, though rare, can be managed with surgical resection and peptide receptor radionuclide therapy (PRRT) targeting somatostatin receptors.

Why it matters

Skin lesions from neuroendocrine tumors can be misdiagnosed, delaying treatment. Recognizing these as metastatic NETs opens the door to targeted peptide therapies (PRRT) that can control even distant disease.

The numbers in context

Single patient case; combination of surgical resection and targeted radionuclide therapy.

How the study worked

Case series documenting cutaneous neuroendocrine metastases of visceral origin, their histologic characterization, and treatment response to surgery and PRRT.

Who was studied

Patient with cutaneous neuroendocrine metastases of visceral origin

What this study cannot tell us

Case series with limited patient numbers — cannot establish response rates or survival benefit. Selection bias toward patients with somatostatin receptor-positive tumors. Generalizability limited to well-differentiated NETs.

How to read the evidence

Preliminary evidence — case series documenting a rare presentation. Valuable for clinical awareness but insufficient for treatment guidelines.

When this study was published

Published in 2024. Reflects current PRRT and NET management approaches.

The bigger picture

PRRT represents one of the clearest successes of peptide-targeted medicine — using the tumor's own somatostatin receptors as a homing beacon for radiation therapy. This case series extends PRRT's demonstrated utility to the uncommon scenario of cutaneous metastases.

Questions still open

Should cutaneous metastases from NETs change staging or prognosis expectations?
Can PRRT prevent further cutaneous metastasis in patients with known visceral NETs?
How should unexplained skin nodules in NET patients be evaluated?

Common questions

Can neuroendocrine tumors spread to the skin?

Yes, though it's very rare. NETs usually spread to the liver, lymph nodes, and lungs. When they do appear in the skin, it typically means the cancer has progressed significantly. However, even these metastases can sometimes be treated with targeted peptide radiation therapy.

What is PRRT and how does it work?

Peptide receptor radionuclide therapy (PRRT) uses radioactive molecules attached to peptides that bind to receptors on tumor cells — specifically somatostatin receptors. It's like a guided missile: the peptide finds the tumor, and the radiation destroys it, while sparing surrounding healthy tissue.

Read the original research

Cutaneous Neuroendocrine Metastases of Visceral Origin Responsive to Surgical Resection and Targeted Radionuclide Therapy.

Case reports in dermatological medicine, 2024, 8873822

View on PubMed ↗Publisher’s paper ↗

Citation

Tung-Hahn, Eleanor; El-Haddad, Ghassan; Strosberg, Jonathan. (2024). Cutaneous Neuroendocrine Metastases of Visceral Origin Responsive to Surgical Resection and Targeted Radionuclide Therapy.. Case reports in dermatological medicine, 2024, 8873822. https://doi.org/10.1155/2024/8873822